Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 03, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed under shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,000,000 ordinary shares of 25 pence each.
- Purchase Price: 1,299.31 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.06% of total voting rights).
- Shares in Issue: 5,232,985,960 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,000,000 repurchased shares. Consequently, the total number of shares in issue was adjusted to 5,232,985,960. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,232,985,960) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (474,194,158) and its percentage of total voting rights (9.06%).
- Note that this filing is a notification of a specific share buyback event and does not contain quarterly or annual financial performance results.